Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.